Phenylketonuria (PKU)

Phenylketonuria is one of the commonest inherited disorders - occurring in approximately 1 in 10,000 babies born in the U. S. It occurs in babies who inherit two mutant genes for the enzyme phenylalanine hydroxylase (PAH). This enzyme normally breaks down molecules of the amino acid phenylalanine that are in excess of the body's needs for protein synthesis.

Because we inherit two copies of the gene for the enzyme, both must be defective to produce the disease. A laboratory test that measures how quickly an injection of phenylalanine is removed from the blood can distinguish a person who has one PKU gene from a person who has none, but the person with one is perfectly healthy because the unmutated allele produces enough of the enzyme. However, these heterozygous individuals are "carriers" of the disease.

The phenylalanine tolerance test. A short time after administering a measured amount of phenylalanine to the subject, the concentration of phenylalanine in the blood plasma is measured. The level is usually substantially higher in people who carry one PKU gene (even though they show no signs of disease) than in individuals who are homozygous for the unmutated gene. Both parents must be heterozygous (i.e., must be "carriers" of the trait) to produce a child with PKU. The chance of their doing so is 1 in 4.

Inability to remove excess phenylalanine from the blood during infancy and early childhood produces a variety of problems including mental retardation. Fortunately, a simple chemical test (done on a wet diaper) shortly after birth can identify the genetic defect and, with close attention to the amount of phenylalanine in their diet, the children can develop normally.

Genetic screening for "a" (NOTE: not "the" - many different mutations in the PKU gene have been identified) PKU allele. Top: schematic of a portion of the gene encoding the enzyme phenylalanine hydroxylase (PAH) showing the sites cut by the restriction enzyme HindIII ("H") and the region to which the radioactive probe binds a mutant version of the gene with a deletion that destroys its function. The deletion eliminates the HindIII site in Exon 2, lengthening the DNA fragment to which the probe binds from 3.3 to 4.2 thousand base pairs (kb) (and thus revealing a RFLP). Middle: The daughter (solid circle) with PKU inherited one PKU allele from each of her parents (half-filled symbols). Her brother (open square) beat the odds (0.5) of inheriting at least one PKU allele and thus of being a carrier. If he had been a carrier, would he have wanted to know? Bottom: The blot shows the fragments to which the probe binds directly beneath each individual in the pedigree. It reveals only the 3.3 kb fragment for the brother, only the 4.2 kb fragment for the sister, and both for each parent. The particular mutation in this family is only one of many mutant PAH alleles that cause PKU, and testing with this particular enzyme and probe would not necessarily detect the others. (Based on the work of Avigad, S., et. al., Nature, 344:168, 1990.)

Phenylalanine hydroxylase (PAH) is made in the liver.

• A child with PKU was cured when he received a transplanted liver (needed for reasons unrelated to his PKU). (Described by Vajro, P., et. al., in the New England Journal of Medicine 329:363, 29 July 1993.)
• Hepatic Nuclear Factor 1 (HNF1) is a transcription factor that is strongly expressed in the cells of the liver (called hepatocytes). In these cells, it binds to and activates the promoters of many genes expressed in the liver. "Knockout" mice were created from embryonic stem (ES) cells carrying two mutant PAH genes.

  Description of the process

  Among other problems, these mice produced no PAH and had severe PKU. (Described by Pontoglio, M., et. al., in Cell 84:575, 23 February 1996.)

Genetic screening

By testing the DNA of prospective parents, their genotype can be determined and their odds of producing an afflicted child can be determined. In the case of PKU, if both parents are heterozygous for the genes, there is a 1 in 4 chance that they will produce a child with the disease.

• Scores of different mutations in the PAH gene can cause the disease. A probe for one will probably fail to identify a second. A mixture of probes, one for each of the more common mutations, can be used. But there remains the problem of "false negatives": people who are falsely told they do not carry a mutant gene.
• With an effective treatment for PKU available, should heterozygous parents forego having children?
• Do they want their health insurance company to know their status?

Dominant or recessive?

The disease PKU is clearly inherited as a recessive trait. Only if one inherits a mutant allele from each parent will one develop the disease.

However, heterozygous people are easily distinguished from homozygotes by the phenylalanine tolerance test. So using the test as the criterion, the PKU allele shows partial dominance.

So, the relationship between genotype and phenotype is not always straightforward. What is the criterion of phenotype in this case? the disease? the results of the tolerance test?